Wobble Genomics Unveils Key Data on HER2 Profiling
Wobble Genomics, an innovative biotechnology firm dedicated to elevating cancer treatment outcomes, is set to present groundbreaking data at the upcoming San Antonio Breast Cancer Symposium (SABCS). This significant event will occur in early December and will showcase their advancements in accurately detecting HER2 expression in breast cancer tissue and blood.
Revolutionary Insights into HER2 Status Detection
The latest findings reveal Wobble's platform can determine HER2 status with impressive precision from breast cancer samples, delivering in-depth isoform-level profiles. Notably, this leads to a correlation between the platform's results and established HER2 immunohistochemistry (IHC) scores, enhancing diagnostic reliability.
The Potential Impact of Long-Read RNA Technology
This study exemplifies the capabilities of Wobble's long-read RNA technology in aiding HER2 targeted therapy selection, particularly from non-invasive blood samples. Such an advancement promises to enhance understanding of transcript diversity and expression patterns.
Improving Treatment Choices for Patients
The implications are clear: this enhanced profiling strategy will empower clinicians to refine therapy choices tailored for breast cancer patients, optimizing their treatment paths significantly. With cancer treatments increasingly reliant on precise biomarkers, this technology could transform the landscape of oncology.
Voices Behind the Research
Dr. Richard Kuo, CEO and Founder of Wobble Genomics, emphasizes the potential of their platform. He states, 'Our research underscores how our innovative approach can revolutionize cancer diagnostics. By providing detailed isoform-level insights into HER2 expression, we enable better-informed therapy choices, leading to safer, personalized patient care.'
Details of the Upcoming Poster Presentation
The detailed information regarding the poster presentation at SABCS includes:
Title: Isoform Level RNA Detection Provides More Detailed Profiling of HER2 Expression in Breast Cancer
Poster Session: Session 4
Date/Time: Scheduled for Thursday, December 11, 2025, from 17:00 – 18:30
Authors: The research has been authored by a talented team, including Jacob Bradley, Yuanyuan Cheng, Katrina Morris, and others, culminating in a comprehensive examination of HER2 profiling technology.
About Wobble Genomics
Wobble Genomics is at the cutting edge of biotechnology, dedicated to advancing cancer diagnostics through long-read cfRNA liquid biopsy techniques. Founded by Dr. Richard Kuo at The Roslin Institute, the company combines expertise in genomics, diagnostics, and oncology. With support from an esteemed advisory panel, Wobble Genomics engages in pivotal clinical studies alongside the National Health Service (NHS) in the UK.
Frequently Asked Questions
What is the main focus of Wobble Genomics?
Wobble Genomics is primarily focused on improving cancer diagnostics, specifically in the area of HER2 profiling to support therapy selection.
When will Wobble Genomics present their findings?
They will present at the San Antonio Breast Cancer Symposium from December 9 to 12, 2025.
What technology does Wobble Genomics utilize?
The company leverages long-read RNA technology to enhance the accuracy of cancer diagnostics and therapy selections.
Who founded Wobble Genomics?
Wobble Genomics was founded by Dr. Richard Kuo at The Roslin Institute.
How does this research benefit cancer patients?
The improved profiling methods aim to enable personalized and precise treatment choices, which could lead to better outcomes for breast cancer patients.
